Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 449

1.

Trajectories of (Bio)markers During the Development of Cognitive Frailty in the Doetinchem Cohort Study.

Rietman ML, Hulsegge G, Nooyens ACJ, Dollé MET, Picavet HSJ, Bakker SJL, Gansevoort RT, Spijkerman AMW, Verschuren WMM.

Front Neurol. 2019 May 31;10:497. doi: 10.3389/fneur.2019.00497. eCollection 2019.

PMID:
31214102
2.

Correction to: Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.

Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans ROB, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJL.

Diabetologia. 2019 Jun 12. doi: 10.1007/s00125-019-4917-y. [Epub ahead of print]

PMID:
31190157
3.

Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors.

Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR, Faber J, Danser AHJ, Gansevoort RT, Rossing P, Persson F, Heerspink HJL.

J Clin Med. 2019 May 31;8(6). pii: E779. doi: 10.3390/jcm8060779.

4.

A catalog of genetic loci associated with kidney function from analyses of a million individuals.

Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, Tin A, Wang L, Chu AY, Hoppmann A, Kirsten H, Giri A, Chai JF, Sveinbjornsson G, Tayo BO, Nutile T, Fuchsberger C, Marten J, Cocca M, Ghasemi S, Xu Y, Horn K, Noce D, van der Most PJ, Sedaghat S, Yu Z, Akiyama M, Afaq S, Ahluwalia TS, Almgren P, Amin N, Ärnlöv J, Bakker SJL, Bansal N, Baptista D, Bergmann S, Biggs ML, Biino G, Boehnke M, Boerwinkle E, Boissel M, Bottinger EP, Boutin TS, Brenner H, Brumat M, Burkhardt R, Butterworth AS, Campana E, Campbell A, Campbell H, Canouil M, Carroll RJ, Catamo E, Chambers JC, Chee ML, Chee ML, Chen X, Cheng CY, Cheng Y, Christensen K, Cifkova R, Ciullo M, Concas MP, Cook JP, Coresh J, Corre T, Sala CF, Cusi D, Danesh J, Daw EW, de Borst MH, De Grandi A, de Mutsert R, de Vries APJ, Degenhardt F, Delgado G, Demirkan A, Di Angelantonio E, Dittrich K, Divers J, Dorajoo R, Eckardt KU, Ehret G, Elliott P, Endlich K, Evans MK, Felix JF, Foo VHX, Franco OH, Franke A, Freedman BI, Freitag-Wolf S, Friedlander Y, Froguel P, Gansevoort RT, Gao H, Gasparini P, Gaziano JM, Giedraitis V, Gieger C, Girotto G, Giulianini F, Gögele M, Gordon SD, Gudbjartsson DF, Gudnason V, Haller T, Hamet P, Harris TB, Hartman CA, Hayward C, Hellwege JN, Heng CK, Hicks AA, Hofer E, Huang W, Hutri-Kähönen N, Hwang SJ, Ikram MA, Indridason OS, Ingelsson E, Ising M, Jaddoe VWV, Jakobsdottir J, Jonas JB, Joshi PK, Josyula NS, Jung B, Kähönen M, Kamatani Y, Kammerer CM, Kanai M, Kastarinen M, Kerr SM, Khor CC, Kiess W, Kleber ME, Koenig W, Kooner JS, Körner A, Kovacs P, Kraja AT, Krajcoviechova A, Kramer H, Krämer BK, Kronenberg F, Kubo M, Kühnel B, Kuokkanen M, Kuusisto J, La Bianca M, Laakso M, Lange LA, Langefeld CD, Lee JJ, Lehne B, Lehtimäki T, Lieb W; Lifelines Cohort Study, Lim SC, Lind L, Lindgren CM, Liu J, Liu J, Loeffler M, Loos RJF, Lucae S, Lukas MA, Lyytikäinen LP, Mägi R, Magnusson PKE, Mahajan A, Martin NG, Martins J, März W, Mascalzoni D, Matsuda K, Meisinger C, Meitinger T, Melander O, Metspalu A, Mikaelsdottir EK, Milaneschi Y, Miliku K, Mishra PP; V. A. Million Veteran Program, Mohlke KL, Mononen N, Montgomery GW, Mook-Kanamori DO, Mychaleckyj JC, Nadkarni GN, Nalls MA, Nauck M, Nikus K, Ning B, Nolte IM, Noordam R, O'Connell J, O'Donoghue ML, Olafsson I, Oldehinkel AJ, Orho-Melander M, Ouwehand WH, Padmanabhan S, Palmer ND, Palsson R, Penninx BWJH, Perls T, Perola M, Pirastu M, Pirastu N, Pistis G, Podgornaia AI, Polasek O, Ponte B, Porteous DJ, Poulain T, Pramstaller PP, Preuss MH, Prins BP, Province MA, Rabelink TJ, Raffield LM, Raitakari OT, Reilly DF, Rettig R, Rheinberger M, Rice KM, Ridker PM, Rivadeneira F, Rizzi F, Roberts DJ, Robino A, Rossing P, Rudan I, Rueedi R, Ruggiero D, Ryan KA, Saba Y, Sabanayagam C, Salomaa V, Salvi E, Saum KU, Schmidt H, Schmidt R, Schöttker B, Schulz CA, Schupf N, Shaffer CM, Shi Y, Smith AV, Smith BH, Soranzo N, Spracklen CN, Strauch K, Stringham HM, Stumvoll M, Svensson PO, Szymczak S, Tai ES, Tajuddin SM, Tan NYQ, Taylor KD, Teren A, Tham YC, Thiery J, Thio CHL, Thomsen H, Thorleifsson G, Toniolo D, Tönjes A, Tremblay J, Tzoulaki I, Uitterlinden AG, Vaccargiu S, van Dam RM, van der Harst P, van Duijn CM, Velez Edward DR, Verweij N, Vogelezang S, Völker U, Vollenweider P, Waeber G, Waldenberger M, Wallentin L, Wang YX, Wang C, Waterworth DM, Bin Wei W, White H, Whitfield JB, Wild SH, Wilson JF, Wojczynski MK, Wong C, Wong TY, Xu L, Yang Q, Yasuda M, Yerges-Armstrong LM, Zhang W, Zonderman AB, Rotter JI, Bochud M, Psaty BM, Vitart V, Wilson JG, Dehghan A, Parsa A, Chasman DI, Ho K, Morris AP, Devuyst O, Akilesh S, Pendergrass SA, Sim X, Böger CA, Okada Y, Edwards TL, Snieder H, Stefansson K, Hung AM, Heid IM, Scholz M, Teumer A, Köttgen A, Pattaro C.

Nat Genet. 2019 Jun;51(6):957-972. doi: 10.1038/s41588-019-0407-x. Epub 2019 May 31.

PMID:
31152163
5.

Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.

Messchendorp AL, Casteleijn NF, Meijer E, Gansevoort RT; DIPAK Consortium investigators .

Nephrol Dial Transplant. 2019 Apr 27. pii: gfz054. doi: 10.1093/ndt/gfz054. [Epub ahead of print]

PMID:
31077332
6.

Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models.

van den Brand JAJG, Dijkstra TMH, Wetzels J, Stengel B, Metzger M, Blankestijn PJ, Lambers Heerspink HJ, Gansevoort RT.

PLoS One. 2019 May 9;14(5):e0216559. doi: 10.1371/journal.pone.0216559. eCollection 2019.

7.

Association between parity and persistent weight gain at age 40-60 years: a longitudinal prospective cohort study.

Zoet GA, Paauw ND, Groenhof K, Franx A, Gansevoort RT, Groen H, Van Rijn B, Lely T.

BMJ Open. 2019 May 5;9(5):e024279. doi: 10.1136/bmjopen-2018-024279.

8.

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators.

Gastroenterology. 2019 Apr 22. pii: S0016-5085(19)36711-3. doi: 10.1053/j.gastro.2019.04.018. [Epub ahead of print]

PMID:
31022403
9.

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

Heerspink HJL, Coresh J, Gansevoort RT, Inker LA.

Lancet Diabetes Endocrinol. 2019 May;7(5):336-337. doi: 10.1016/S2213-8587(19)30080-4. No abstract available.

PMID:
31003622
10.

Muscle mass determined from urinary creatinine excretion rate, and muscle performance in renal transplant recipients.

Stam SP, Eisenga MF, Gomes-Neto AW, van Londen M, de Meijer VE, van Beek AP, Gansevoort RT, Bakker SJL.

J Cachexia Sarcopenia Muscle. 2019 Mar 25. doi: 10.1002/jcsm.12399. [Epub ahead of print]

11.

Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States.

Ishigami J, Padula WV, Grams ME, Chang AR, Jaar B, Gansevoort RT, Bridges JFP, Kovesdy CP, Uchida S, Coresh J, Matsushita K.

Am J Kidney Dis. 2019 Mar 19. pii: S0272-6386(19)30132-5. doi: 10.1053/j.ajkd.2019.01.025. [Epub ahead of print]

PMID:
30898360
12.

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators.

Kidney Int. 2019 Mar 9. pii: S0085-2538(19)30041-9. doi: 10.1016/j.kint.2018.11.044. [Epub ahead of print]

PMID:
30898339
13.

Stability of tubular damage markers epidermal growth factor and heparin-binding EGF-like growth factor in urine.

Harskamp LR, Meijer E, van Goor H, Engels GE, Gansevoort RT.

Clin Chem Lab Med. 2019 Mar 5. pii: /j/cclm.ahead-of-print/cclm-2019-0152/cclm-2019-0152.xml. doi: 10.1515/cclm-2019-0152. [Epub ahead of print] No abstract available.

PMID:
30835251
14.

Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk.

Corsetti JP, Bakker SJL, Gansevoort RT, Gruppen EG, Connelly MA, Sparks CE, Dullaart RPF.

Int J Mol Sci. 2019 Feb 23;20(4). pii: E977. doi: 10.3390/ijms20040977.

15.

Genome-Wide Association Scan of Serum Urea in European Populations Identifies Two Novel Loci.

Thio CHL, Reznichenko A, van der Most PJ, Kamali Z, Vaez A, Smit JH, Penninx BWJH, Haller T, Mihailov E, Metspalu A, Damman J, de Borst MH, van der Harst P, Verweij N, Navis GJ, Gansevoort RT, Nolte IM, Snieder H; Lifelines Cohort Study group.

Am J Nephrol. 2019;49(3):193-202. doi: 10.1159/000496930. Epub 2019 Feb 26.

16.

Body fat estimates from bioelectrical impedance equations in cardiovascular risk assessment: The PREVEND cohort study.

Byambasukh O, Eisenga MF, Gansevoort RT, Bakker SJ, Corpeleijn E.

Eur J Prev Cardiol. 2019 Jun;26(9):905-916. doi: 10.1177/2047487319833283. Epub 2019 Feb 21.

PMID:
30791699
17.

Lower Plasma Magnesium, Measured by Nuclear Magnetic Resonance Spectroscopy, is Associated with Increased Risk of Developing Type 2 Diabetes Mellitus in Women: Results from a Dutch Prospective Cohort Study.

Schutten JC, Gomes-Neto AW, Navis G, Gansevoort RT, Dullaart RPF, Kootstra-Ros JE, Danel RM, Goorman F, Gans ROB, de Borst MH, Jeyarajah EJ, Shalaurova I, Otvos JD, Connelly MA, Bakker SJL.

J Clin Med. 2019 Feb 1;8(2). pii: E169. doi: 10.3390/jcm8020169.

18.

A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.

Simms RJ, Doshi T, Metherall P, Ryan D, Wright P, Gruel N, van Gastel MDA, Gansevoort RT, Tindale W, Ong ACM.

Eur Radiol. 2019 Jan 21. doi: 10.1007/s00330-018-5918-9. [Epub ahead of print]

PMID:
30666443
19.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

PMID:
30635226
20.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.

PMID:
30635225
21.

Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium.

Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M; CKD Prognosis Consortium (CKD-PC).

BMJ. 2019 Jan 10;364:k5301. doi: 10.1136/bmj.k5301.

22.

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.

Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT.

Am J Kidney Dis. 2019 Mar;73(3):354-362. doi: 10.1053/j.ajkd.2018.09.016. Epub 2018 Dec 19.

PMID:
30578153
23.

Trajectory of Cardiovascular Risk Factors After Hypertensive Disorders of Pregnancy.

Groenhof TKJ, Zoet GA, Franx A, Gansevoort RT, Bots ML, Groen H, Lely AT; PREVEND Group.

Hypertension. 2019 Jan;73(1):171-178. doi: 10.1161/HYPERTENSIONAHA.118.11726.

PMID:
30571544
24.

Treatable Vascular Risk and Cognitive Performance in Persons Aged 35 Years or Older: Longitudinal Study of Six Years.

van Eersel MEA, Joosten H, Gansevoort RT, Slaets JPJ, Izaks GJ.

J Prev Alzheimers Dis. 2019;6(1):42-49. doi: 10.14283/jpad.2018.47.

25.

Educational level and risk of chronic kidney disease: longitudinal data from the PREVEND study.

Thio CHL, Vart P, Kieneker LM, Snieder H, Gansevoort RT, Bültmann U.

Nephrol Dial Transplant. 2018 Dec 12. doi: 10.1093/ndt/gfy361. [Epub ahead of print]

PMID:
30541108
26.

Changes in cerebral oxygenation and cerebral blood flow during hemodialysis - A simultaneous near-infrared spectroscopy and positron emission tomography study.

Polinder-Bos HA, Elting JWJ, Aries MJ, García DV, Willemsen AT, van Laar PJ, Kuipers J, Krijnen WP, Slart RH, Luurtsema G, Westerhuis R, Gansevoort RT, Gaillard CA, Franssen CF.

J Cereb Blood Flow Metab. 2018 Dec 12:271678X18818652. doi: 10.1177/0271678X18818652. [Epub ahead of print]

PMID:
30540219
27.

Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies.

Pennells L, Kaptoge S, Wood A, Sweeting M, Zhao X, White I, Burgess S, Willeit P, Bolton T, Moons KGM, van der Schouw YT, Selmer R, Khaw KT, Gudnason V, Assmann G, Amouyel P, Salomaa V, Kivimaki M, Nordestgaard BG, Blaha MJ, Kuller LH, Brenner H, Gillum RF, Meisinger C, Ford I, Knuiman MW, Rosengren A, Lawlor DA, Völzke H, Cooper C, Marín Ibañez A, Casiglia E, Kauhanen J, Cooper JA, Rodriguez B, Sundström J, Barrett-Connor E, Dankner R, Nietert PJ, Davidson KW, Wallace RB, Blazer DG, Björkelund C, Donfrancesco C, Krumholz HM, Nissinen A, Davis BR, Coady S, Whincup PH, Jørgensen T, Ducimetiere P, Trevisan M, Engström G, Crespo CJ, Meade TW, Visser M, Kromhout D, Kiechl S, Daimon M, Price JF, Gómez de la Cámara A, Wouter Jukema J, Lamarche B, Onat A, Simons LA, Kavousi M, Ben-Shlomo Y, Gallacher J, Dekker JM, Arima H, Shara N, Tipping RW, Roussel R, Brunner EJ, Koenig W, Sakurai M, Pavlovic J, Gansevoort RT, Nagel D, Goldbourt U, Barr ELM, Palmieri L, Njølstad I, Sato S, Monique Verschuren WM, Varghese CV, Graham I, Onuma O, Greenland P, Woodward M, Ezzati M, Psaty BM, Sattar N, Jackson R, Ridker PM, Cook NR, D'Agostino RB, Thompson SG, Danesh J, Di Angelantonio E; Emerging Risk Factors Collaboration.

Eur Heart J. 2019 Feb 14;40(7):621-631. doi: 10.1093/eurheartj/ehy653.

28.

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators.

JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870.

29.

Too much nephrology? The CKD epidemic is real and concerning. A PRO view.

Gansevoort RT.

Nephrol Dial Transplant. 2019 Apr 1;34(4):577-580. doi: 10.1093/ndt/gfy330.

PMID:
30418646
30.

Albuminuria as a cause of hypertension.

Gansevoort RT, Snieder H.

Nat Rev Nephrol. 2019 Jan;15(1):6-8. doi: 10.1038/s41581-018-0073-8. No abstract available.

PMID:
30348952
31.

Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.

Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, Gansevoort RT, Gutierrez OM, Hamano T, Heine GH, Ishikawa S, Jee SH, Kronenberg F, Landray MJ, Miura K, Nadkarni GN, Peralta CA, Rothenbacher D, Schaeffner E, Sedaghat S, Shlipak MG, Zhang L, van Zuilen AD, Hallan SI, Kovesdy CP, Woodward M, Levin A; CKD Prognosis Consortium.

Am J Kidney Dis. 2019 Feb;73(2):206-217. doi: 10.1053/j.ajkd.2018.08.013. Epub 2018 Oct 19.

PMID:
30348535
32.

Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.

Messchendorp AL, van Londen M, Taylor JM, de Borst MH, Navis G, Casteleijn NF, Gaillard CAJM, Bakker SJL, Gansevoort RT; DIPAK Consortium.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1680-1692. doi: 10.2215/CJN.03650318. Epub 2018 Sep 25.

PMID:
30254028
33.

Association of Low Urinary Sodium Excretion With Increased Risk of Stroke.

Kieneker LM, Eisenga MF, Gansevoort RT, de Boer RA, Navis G, Dullaart RPF, Joosten MM, Bakker SJL.

Mayo Clin Proc. 2018 Dec;93(12):1803-1809. doi: 10.1016/j.mayocp.2018.05.028. Epub 2018 Sep 20.

PMID:
30244812
34.

Publisher Correction: Lower body mass index and mortality in older adults starting dialysis.

Polinder-Bos HA, van Diepen M, Dekker FW, Hoogeveen EK, Franssen CFM, Gansevoort RT, Gaillard CAJM.

Sci Rep. 2018 Sep 18;8(1):14231. doi: 10.1038/s41598-018-32555-3.

35.

Lower body mass index and mortality in older adults starting dialysis.

Polinder-Bos HA, Diepen MV, Dekker FW, Hoogeveen EK, Franssen CFM, Gansevoort RT, Gaillard CAJM.

Sci Rep. 2018 Aug 27;8(1):12858. doi: 10.1038/s41598-018-30952-2. Erratum in: Sci Rep. 2018 Sep 18;8(1):14231.

36.

Effect of plasma sodium concentration on blood pressure regulators during hemodialysis: a randomized crossover study.

Ettema EM, Kuipers J, van Faassen M, Groen H, van Roon AM, Lefrandt JD, Westerhuis R, Kema IP, van Goor H, Gansevoort RT, Gaillard CAJM, Franssen CFM.

BMC Nephrol. 2018 Aug 22;19(1):214. doi: 10.1186/s12882-018-0997-z.

37.

[Chronic kidney damage guidelines revision].

Hemmelder MH, van Balen J, Scherpbier N, Schenk PW, Tuut MK, Gansevoort RT.

Ned Tijdschr Geneeskd. 2018 Jun 14;162. pii: D2974. Dutch.

PMID:
30040336
38.

Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver disease.

Lantinga MA, de Sévaux RGL, Gevers TJG, Oyen WJG, de Fijter JW, Soonawala D, Zietse R, Salih M, Casteleijn NF, Spithoven EM, Meijer E, Gansevoort RT, Drenth On Behalf Of The Dipak Consortium JPH.

Neth J Med. 2018 Jul;76(5):226-234.

39.

The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF.

Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, Kizer JR, Sarma A, Blaha MJ, Gansevoort RT, Gardin JM, Hillege HL, Ji F, Kop WJ, Lau ES, Lee DS, Sadreyev R, van Gilst WH, Wang TJ, Zanni MV, Vasan RS, Allen NB, Psaty BM, van der Harst P, Levy D, Larson M, Shah SJ, de Boer RA, Gottdiener JS, Ho JE.

JACC Heart Fail. 2018 Aug;6(8):701-709. doi: 10.1016/j.jchf.2018.05.018. Epub 2018 Jul 11.

PMID:
30007554
40.

Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.

El Boustany R, Tasevska I, Meijer E, Kieneker LM, Enhörning S, Lefèvre G, Mohammedi K, Marre M, Fumeron F, Balkau B, Bouby N, Bankir L, Bakker SJ, Roussel R, Melander O, Gansevoort RT, Velho G.

JCI Insight. 2018 Jul 12;3(13). pii: 121479. doi: 10.1172/jci.insight.121479.

41.

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan.

Kramers BJ, van Gastel MDA, Meijer E, Gansevoort RT.

BMC Nephrol. 2018 Jul 3;19(1):157. doi: 10.1186/s12882-018-0957-7.

42.

Urinary Excretion of Sulfur Metabolites and Risk of Cardiovascular Events and All-Cause Mortality in the General Population.

van den Born JC, Frenay AS, Koning AM, Bachtler M, Riphagen IJ, Minovíc I, Feelisch M, Dekker MM, Bulthuis MLC, Gansevoort RT, Hillebrands JL, Pasch A, Bakker SJL, van Goor H.

Antioxid Redox Signal. 2019 Jun 10;30(17):1999-2010. doi: 10.1089/ars.2017.7040. Epub 2018 Jul 25.

PMID:
29905081
43.

Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA.

Eur J Heart Fail. 2018 Aug;20(8):1205-1214. doi: 10.1002/ejhf.1209. Epub 2018 Jun 1.

PMID:
29855124
44.

Risk Factors for Prognosis in Patients With Severely Decreased GFR.

Evans M, Grams ME, Sang Y, Astor BC, Blankestijn PJ, Brunskill NJ, Collins JF, Kalra PA, Kovesdy CP, Levin A, Mark PB, Moranne O, Rao P, Rios PG, Schneider MP, Shalev V, Zhang H, Chang AR, Gansevoort RT, Matsushita K, Zhang L, Eckardt KU, Hemmelgarn B, Wheeler DC.

Kidney Int Rep. 2018 Jan 11;3(3):625-637. doi: 10.1016/j.ekir.2018.01.002. eCollection 2018 May. Erratum in: Kidney Int Rep. 2018 Aug 30;3(6):1506.

45.

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.

Messchendorp AL, Meijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM, Losekoot M, Burgerhof JGM, Peters DJM, Gansevoort RT; DIPAK Consortium.

Kidney Int Rep. 2017 Oct 14;3(2):291-301. doi: 10.1016/j.ekir.2017.10.004. eCollection 2018 Mar.

46.

Self-Reported Smoking, Urine Cotinine, and Risk of Cardiovascular Disease: Findings From the PREVEND (Prevention of Renal and Vascular End-Stage Disease) Prospective Cohort Study.

Kunutsor SK, Spee JM, Kieneker LM, Gansevoort RT, Dullaart RPF, Voerman AJ, Touw DJ, Bakker SJL.

J Am Heart Assoc. 2018 May 2;7(10). pii: e008726. doi: 10.1161/JAHA.118.008726.

47.

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

Dekkers CCJ, Gansevoort RT, Heerspink HJL.

Curr Diab Rep. 2018 Mar 27;18(5):27. doi: 10.1007/s11892-018-0992-6. Review.

48.

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.

Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL.

Diabetes Obes Metab. 2018 Aug;20(8):1988-1993. doi: 10.1111/dom.13301. Epub 2018 Apr 23.

49.

Hemodialysis Induces an Acute Decline in Cerebral Blood Flow in Elderly Patients.

Polinder-Bos HA, García DV, Kuipers J, Elting JWJ, Aries MJH, Krijnen WP, Groen H, Willemsen ATM, van Laar PJ, Strijkert F, Luurtsema G, Slart RHJA, Westerhuis R, Gansevoort RT, Gaillard CAJM, Franssen CFM.

J Am Soc Nephrol. 2018 Apr;29(4):1317-1325. doi: 10.1681/ASN.2017101088. Epub 2018 Mar 1. Erratum in: J Am Soc Nephrol. 2018 Aug;29(8):2256.

50.

Proenkephalin and risk of developing chronic kidney disease: the Prevention of Renal and Vascular End-stage Disease study.

Kieneker LM, Hartmann O, Bergmann A, de Boer RA, Gansevoort RT, Joosten MM, Struck J, Bakker SJL.

Biomarkers. 2018 Jul;23(5):474-482. doi: 10.1080/1354750X.2018.1443514. Epub 2018 Mar 8.

PMID:
29466891

Supplemental Content

Loading ...
Support Center